Metabolic disorders such as argininosuccinic and glutaric aciduria, methylmalonic acidemia, homocystinuria or primary hyperoxaluria require specific diets to prevent the accumulation of substances ...

Despite its expensive valuation and declining estimates, we suggest investors hold LLY stock as the company boasts solid ...

Work at Scorpion Therapeutics Inc. has led to the identification of cellular tumor antigen p53 (TP53) (Y220C mutant) activators reported to be useful for the treatment of cancer.

Eli Lilly & Co has experienced a significant stock price drop of 10.58% over the past week, despite delivering impressive first-quarter results for 2025. The company’s revenue s ...

Overall, Wall Street has a Strong Buy consensus rating on Eli Lilly stock based on 18 Buys and one Sell recommendation. The average LLY stock price target of $981 implies about 26.6% upside potential.

Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to ...

Eli Lilly and Company (NYSE: LLY) today announced its financial results for the first-quarter of 2025.

If you ever find yourself staring down this venomous Texas dweller, be careful. Statistics strongly suggest that it's better ...

MEMPHIS, Tenn. — The trial for three former Memphis Police officers continues on Thursday with ex-Scorpion Unit officer Preston Hemphill’s testimony on the night Tyre Nichols was beaten to death.

which is primarily related to its acquisition of a certain oral cancer drug from Scorpion Therapeutics. Get top local Connecticut stories delivered to you every morning with the News Headlines ...

These moves, starting with DICE Therapeutics in mid-2023 and most recently Scorpion Therapeutics in early 2025, are helping the company grow into new areas. On April 21, Evan Seigerman of BMO ...

LLY has delivered impressive returns of 15% year-to-date (as of April 30), outperforming the S&P 500’s 5% decline during the ...